Market Research Logo

Boehringer Ingelheim GmbH - Strategic SWOT Analysis Review

Boehringer Ingelheim GmbH - Strategic SWOT Analysis Review

- provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – GlobalData’s summarization of the company’s business strategy.
  • SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
Highlights

Boehringer Ingelheim GmbH (Boehringer), a subsidiary of CH Boehringer Sohn AG & Co KG is a pharmaceutical company that conducts research, development, manufacture and sale of pharmaceuticals. It offers a wide range of products including human diseases, animal health care products and biopharmaceuticals. The company’s products are used in the treatment of central nervous system disorders, respiratory diseases, cardiovascular diseases, metabolic disorders, cancer, urological and viral conditions, among others. It operates facilities for manufacture pharmaceuticals, chemical active substances, and medical products. Boehringer operates globally through affiliates and is headquartered in Ingelheim am Rhein, Rheinland-Pfalz, Germany.

Boehringer Ingelheim GmbH Key Recent Developments

Aug 07,2018: Boehringer forms new alliance to develop gene therapy
Aug 06,2018: Researchers partner with industry to develop ground-breaking gene therapy for CF
Aug 02,2018: Boehringer Ingelheim launches the initiative In Reach Africa to address key healthcare infrastructure and access priorities across Africa
Aug 01,2018: Boehringer Ingelheim achieves modest growth in the first half of 2018
Jul 14,2018: Boehringer Ingelheim unveils 15 new medicines

Reasons to Buy
  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
    • Note: Some sections may be missing if data is unavailable for the company.


Section 1 - About the Company
Boehringer Ingelheim GmbH - Key Facts
Boehringer Ingelheim GmbH - Key Employees
Boehringer Ingelheim GmbH - Key Employee Biographies
Boehringer Ingelheim GmbH - Major Products and Services
Boehringer Ingelheim GmbH - History
Boehringer Ingelheim GmbH - Company Statement
Boehringer Ingelheim GmbH - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Boehringer Ingelheim GmbH - Business Description
Business Segment: Animal Health
Overview
Performance
Key Stats
Business Segment: Biopharmaceuticals
Overview
Performance
Key Stats
Business Segment: Discontinued Operations
Performance
Business Segment: Human Pharmaceuticals
Overview
Performance
Business Segment: Industrial Customers and Other Sales
Overview
Performance
Geographical Segment: Americas
Performance
Geographical Segment: Asia/Australia/Africa
Performance
Geographical Segment: Europe
Performance
R&D Overview
Boehringer Ingelheim GmbH - Corporate Strategy
Boehringer Ingelheim GmbH - SWOT Analysis
SWOT Analysis - Overview
Boehringer Ingelheim GmbH - Strengths
Boehringer Ingelheim GmbH - Weaknesses
Boehringer Ingelheim GmbH - Opportunities
Boehringer Ingelheim GmbH - Threats
Boehringer Ingelheim GmbH - Key Competitors
Section 3 – Company’s Lifesciences Financial Deals and Alliances
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Boehringer Ingelheim GmbH, Recent Deals Summary
Section 4 – Company’s Recent Developments
Aug 06, 2018: Researchers partner with industry to develop ground-breaking gene therapy for CF
Aug 02, 2018: Boehringer Ingelheim launches the initiative In Reach Africa to address key healthcare infrastructure and access priorities across Africa
Aug 01, 2018: Boehringer Ingelheim achieves modest growth in the first half of 2018
Jul 11, 2018: Boehringer Ingelheim acquires MabVax’s programme for solid tumours
Jul 04, 2018: Boehringer Ingelheim extends “one-stop-shop” service with new fill & finish capabilities in China
May 23, 2018: Big Pharma CMOs Win for Biologic API and Alcami Scores Highest for Biologic Drug Product
Apr 25, 2018: Boehringer Ingelheim has a very successful 2017 financial year
Apr 25, 2018: Boehringer Ingelheim RD pushes to transcend disease boundaries
Apr 24, 2018: Topas Therapeutics and Boehringer Ingelheim Sign Multi-Year Collaboration and Option Agreement
Apr 11, 2018: Investment Of 65 Million Euro In Avian Vaccines In France
Section 5 – Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Boehringer Ingelheim GmbH, Key Facts
Boehringer Ingelheim GmbH, Key Employees
Boehringer Ingelheim GmbH, Key Employee Biographies
Boehringer Ingelheim GmbH, Major Products and Services
Boehringer Ingelheim GmbH, History
Boehringer Ingelheim GmbH, Other Locations
Boehringer Ingelheim GmbH, Subsidiaries
Boehringer Ingelheim GmbH, Key Competitors
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Boehringer Ingelheim GmbH, Recent Deals Summary
List of Figures
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report